EHA: European Hematology Association
Conference Coverage
Activin receptors continue to show efficacy in ß-thalassemia
Congress of the European Hematology Association VIENNA—Two very similar activin receptors, luspatercept and sotatercept, continue to show...
Conference Coverage
Drug won’t advance to phase 3 in ß-thalassemia
thalassemia VIENNA—Data from a phase 2a trial suggest the activin receptor sotatercept can effectively treat patients with ß-thalassemia....
Conference Coverage
Jury still out on combo for elderly AML
Photo courtesy of NIH VIENNA—A 2-drug combination can produce complete responses (CRs) in elderly patients with newly diagnosed acute myeloid...
Conference Coverage
Combo delays progression in relapsed CLL
VIENNA—Results of the COMPLEMENT 2 trial indicate that adding ofatumumab to treatment with fludarabine and cyclophosphamide (OFC) can improve some...
Conference Coverage
Triplet can provide clinical benefit in rel/ref MM
VIENNA—Combination therapy consisting of the HDAC6 inhibitor ricolinostat, pomalidomide, and dexamethasone can provide a clinical benefit for...
Conference Coverage
Unsickling red blood cells
VIENNA—Researchers say they have found a way to unsickle red blood cells (RBCs), at least in vitro. Using pegylated carboxyhemoglobin bovine gas...
Conference Coverage
Dose reductions make ponatinib safer for CP-CML
VIENNA—Administering ponatinib at lower doses can reduce the risk of arterial occlusive events (AOE) without hindering responses in patients with...
Conference Coverage
Drug may be ‘important treatment option’ for AML
Photo courtesy of ASH VIENNA—Adding the anticancer quinolone derivative vosaroxin to treatment with cytarabine can improve outcomes for some...
Conference Coverage
mAb produces responses in AL amyloidosis
VIENNA—A monoclonal antibody (mAb) can produce responses in patients with light chain (AL) amyloidosis and persistent organ dysfunction, according...
Conference Coverage
JAK inhibitor can provide long-term disease control in PV
Image courtesy of AFIP VIENNA—Updated results from the phase 3 RESPONSE trial suggest the JAK1/2 inhibitor ruxolitinib can provide long-term...
Conference Coverage
EHA: Dasatinib gets early edge over imatinib in CML
Key clinical point: Dasatinib provides more molecular responses than imatinib, but no survival advantage at 2 years in the first-line treatment of...
Conference Coverage
EHA: Venetoclax-rituxumab combo highly active in relapsed/refractory CLL
Key clinical point: Venetoclax plus rituximab is a highly active nonchemotherapy combination for patients with relapsed or refractory chronic...
Conference Coverage
VIDEO: Are chemo-free regimens possible for CLL?
Conference Coverage
VIDEO: ABT-199 alone and in combination shows promise against advanced CLL
Conference Coverage
Depth of molecular response factors into safe TKI withdrawal in CML
Key clinical point: Long-time TKI therapy can be stopped in chronic myeloid leukemia in deep molecular remission.